CARBOGEN AMCIS opens new liquid drug product manufacturing facility

The Switzerland-based pharmaceutical process and ingredient developer and manufacturer announced the opening of their new sterile liquid drug product manufacturing facility in France.

Construction of the facility began January 2021, and will be dedicated to custom development, manufacturing, and production of sterile injectable drugs and therapeutics. Through the new site, CARBOGEN AMICS’ capacity will also increase for product development and manufacturing of liquid and freeze-dried products for use in preclinical and clinical trials, as well as small-scale commercial use. The facility is located 7 km away from an existing CABOGEN AMCIS site in Riom. 

With over 15 years of experience, the new CARBOGEN AMCIS facility will include two fully automated production lines for either liquid or freeze-dried drug products, with capacity to handle highly potent compounds and advance therapies, including antibody–drug conjugates. The company hopes to fill a need within the European pharmaceutical market for securing fill-finish capacity with flexible set-ups. The opening of this new facility will also create 50 new jobs throughout 2023, and employ approximately 100 highly skilled individuals. CARBOGEN AMCIS already operate nine sites across Europe, Switzerland, the UK, and China. 

CEO of CARBOGEN AMCIS Pascal Villemagne commented on the opening: “Over the last 6 years, CARBOGEN AMCIS has continued to expand our facilities and grow our capacity, enabling us to support more customers and increase access to new and diverse technologies and services. Our new site will enable us to fully synergize our world-class chemistry skills and continue to bring our customers’ science to life, helping us play our part in the roll-out of new and better treatments, which help improve patients’ quality of life or treat otherwise terminal illness.” 

Adding onto Villemagne’s comments, François Baduel, VP of Business Development, Sales, and Marketing of CARBOGEN AMCIS stated that “The opening of our new site in France signals an exciting time for us as we enhance our capacity to provide seamless drug product development and commercialisation services for leading pharmaceutical and biopharmaceutical companies on a global scale. Applying state-of-the-art containment technologies, our new site in France cements us as the partner of choice for [the] development and [manufacturing] of drug products.”